Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Apr;36(4):833–839. doi: 10.1128/aac.36.4.833

Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia.

C Carbon 1, P Léophonte 1, P Petitpretz 1, J P Chauvin 1, J Hazebroucq 1
PMCID: PMC189443  PMID: 1323954

Abstract

Temafloxacin, a new fluoroquinolone, was compared with amoxicillin in the treatment of adult hospitalized patients with community-acquired pneumonia. In this double-blind, multicenter study, patients were randomly assigned to treatment with temafloxacin at 600 mg twice daily (n = 125) or amoxicillin at 500 mg three times daily (n = 121); the average duration of treatment was 10 days. Clinical recovery rates were similar for patients treated with temafloxacin and amoxicillin (89 and 85%), as were bacterial eradication rates (99 and 97%). This was also true for subgroups of patients with pneumococcal pneumonia (n = 100), nonpneumococcal pneumonia (n = 122), or atypical pneumonia (n = 12). Outcomes for temafloxacin- and amoxicillin-treated patients were also similar in terms of defervescence, improvement in leukocytosis, and radiographic evidence of infection. The frequency and severity of adverse events were similar in both groups, consisting primarily of digestive disorders and skin manifestations. We conclude that temafloxacin may be recommended as an alternative antibacterial drug for patients with suspected pneumococcal pneumonia who fail to respond to benzylpenicillin or amoxicillin when the incidence of multiresistant pneumococcal strains is low. In countries where the incidence of these strains is high, temafloxacin may also be recommended.

Full text

PDF
833

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azoulay-Dupuis E., Bedos J. P., Vallée E., Hardy D. J., Swanson R. N., Pocidalo J. J. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis. 1991 Feb;163(2):319–324. doi: 10.1093/infdis/163.2.319. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Jones R. N. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. J Antimicrob Chemother. 1989 Apr;23(4):527–535. doi: 10.1093/jac/23.4.527. [DOI] [PubMed] [Google Scholar]
  3. Berntsson E., Blomberg J., Lagergård T., Trollfors B. Etiology of community-acquired pneumonia in patients requiring hospitalization. Eur J Clin Microbiol. 1985 Jun;4(3):268–272. doi: 10.1007/BF02013650. [DOI] [PubMed] [Google Scholar]
  4. Berntsson E., Lagergård T., Strannegård O., Trollfors B. Etiology of community-acquired pneumonia in out-patients. Eur J Clin Microbiol. 1986 Aug;5(4):446–447. doi: 10.1007/BF02075702. [DOI] [PubMed] [Google Scholar]
  5. Casal J., Fenoll A., Vicioso M. D., Muñoz R. Increase in resistance to penicillin in pneumococci in Spain. Lancet. 1989 Apr 1;1(8640):735–735. doi: 10.1016/s0140-6736(89)92260-5. [DOI] [PubMed] [Google Scholar]
  6. Fang G. D., Fine M., Orloff J., Arisumi D., Yu V. L., Kapoor W., Grayston J. T., Wang S. P., Kohler R., Muder R. R. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990 Sep;69(5):307–316. doi: 10.1097/00005792-199009000-00004. [DOI] [PubMed] [Google Scholar]
  7. Finch R. Treatment of respiratory tract infections with cephalosporin antibiotics. Drugs. 1987;34 (Suppl 2):180–204. doi: 10.2165/00003495-198700342-00014. [DOI] [PubMed] [Google Scholar]
  8. Foy H. M., Wentworth B., Kenny G. E., Kloeck J. M., Grayston J. T. Pneumococcal isolations from patients with pneumonia and control subjects in a prepaid medical care group. Am Rev Respir Dis. 1975 May;111(5):595–603. doi: 10.1164/arrd.1975.111.5.595. [DOI] [PubMed] [Google Scholar]
  9. Granados A., Podzamczer D., Gudiol F., Manresa F. Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: similarities and differences on presentation. Eur Respir J. 1989 Feb;2(2):130–134. [PubMed] [Google Scholar]
  10. Grayston J. T. Chlamydia pneumoniae, strain TWAR. Chest. 1989 Mar;95(3):664–669. doi: 10.1378/chest.95.3.664. [DOI] [PubMed] [Google Scholar]
  11. Klugman K. P. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990 Apr;3(2):171–196. doi: 10.1128/cmr.3.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lévy M., Dromer F., Brion N., Leturdu F., Carbon C. Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations. Chest. 1988 Jan;93(1):43–48. doi: 10.1378/chest.93.1.43. [DOI] [PubMed] [Google Scholar]
  13. Macfarlane J. T., Finch R. G., Ward M. J., Macrae A. D. Hospital study of adult community-acquired pneumonia. Lancet. 1982 Jul 31;2(8292):255–258. doi: 10.1016/s0140-6736(82)90334-8. [DOI] [PubMed] [Google Scholar]
  14. Macfarlane J. T., Miller A. C., Roderick Smith W. H., Morris A. H., Rose D. H. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax. 1984 Jan;39(1):28–33. doi: 10.1136/thx.39.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Marrie T. J., Durant H., Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis. 1989 Jul-Aug;11(4):586–599. doi: 10.1093/clinids/11.4.586. [DOI] [PubMed] [Google Scholar]
  16. Marton A., Gulyas M., Munoz R., Tomasz A. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis. 1991 Mar;163(3):542–548. doi: 10.1093/infdis/163.3.542. [DOI] [PubMed] [Google Scholar]
  17. Mazzulli T., Simor A. E., Jaeger R., Fuller S., Low D. E. Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1990 Mar;34(3):467–469. doi: 10.1128/aac.34.3.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Murray P. R., Washington J. A. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975 Jun;50(6):339–344. [PubMed] [Google Scholar]
  19. Nye K., Shi Y. G., Andrews J. M., Ashby J. P., Wise R. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother. 1989 Sep;24(3):415–424. doi: 10.1093/jac/24.3.415. [DOI] [PubMed] [Google Scholar]
  20. Safran C. Cefpodoxime proxetil: dosage, efficacy and tolerance in adults suffering from respiratory tract infections. J Antimicrob Chemother. 1990 Dec;26 (Suppl E):93–101. doi: 10.1093/jac/26.suppl_e.93. [DOI] [PubMed] [Google Scholar]
  21. White R. J., Blainey A. D., Harrison K. J., Clarke S. K. Causes of pneumonia presenting to a district general hospital. Thorax. 1981 Aug;36(8):566–570. doi: 10.1136/thx.36.8.566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Woodhead M. A., Macfarlane J. T., McCracken J. S., Rose D. H., Finch R. G. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987 Mar 21;1(8534):671–674. doi: 10.1016/s0140-6736(87)90430-2. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES